eurovalve 2016 program
Post on 23-Jul-2016
233 Views
Preview:
DESCRIPTION
TRANSCRIPT
March 10 - 11, 2016
www.eu rova l vecong ress .com
Hotel Bloom!, Brussels, BELGIUM
COURSE DIRECTORSPatrizio Lancellotti, Liege, Belgium
Khalil Fattouch, Palermo, ItalyGilbert Habib, Marseille, France
José Luis Zamorano, Madrid, SpainRaphael Rosenhek, Vienna, Austria
Scientific program endorsed by the EACVIand by the ESC Working Group on Valvular Heart Diseases
Edito
Welcome to EuroValve 2016!
It is a great pleasure to welcome you for this fourth edition in Brussels, the n°1 destination for congresses in Europe, which offers you an exciting cultural, artistic and socialscene at sensible prices.As you may know, we always intend to favour more interactivity and discussions, especially thanks to several symposia, industry symposia, controversies and round tables.Again, over 2 days, we will present an extensive program dedicated to valvular heart disease, focusing on genetics, surgery, epidemiology, transcatheter valve replacement, echocardiography and new imaging.This year, we are hosting the ePosters presentation on Thursday March 10 in the plenary room.Take your time to visit the exhibition and discover the Industry news as it is only thanks to their precious help that we could achieve our ambitious program and do not miss Abbott Vascular and Siemens symposia in the plenary room.We are very pleased to have you during two convivial days of fruitful teaching in Brussels.
Enjoy the congress!The course directors
Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib,José Luis Zamorano and Raphael Rosenhek
FacultyJutta Bergler-Klein, Vienna, AustriaAlain Berrebi, Paris, FranceBernard Cosyns, Braine-L’Alleud, BelgiumMichele De Bonis, Milan, ItalyJean-Olivier Defraigne, Liege, BelgiumLaurent De Kerchove, Woluwe-Saint-Lambert, BelgiumVictoria Delgado, Leiden, The NetherlandsAlessandro Della Corte, Naples, ItalyErwan Donal, Rennes, FranceGilles Dreyfus, MonacoRaluca Elena Dulgheru, Brussels, BelgiumArturo Evangelista Masip, Barcelona, SpainMadalina Garbi, London, United KingdomAriana González-Gómez, Madrid, SpainBernard Iung, Paris, FranceJoëlle Kefer, Brussels, BelgiumPhilippe Kolh, Liege, BelgiumGiovanni La Canna, Milan, ItalyVictor Legrand, Liege, Belgium
Julien Magne, Limoges, FranceGérald Maurer, Vienna, AustriaThomas Modine, Lille, FranceJean-Luc Monin, Créteil, FranceCécile Oury, Liege, BelgiumAlessandro Parolari, Milan, ItalyAgnes Pasquet, Brussels, BelgiumPhilippe Pibarot, Quebec, CanadaLuc Piérard, Liege, BelgiumBernard Prendergast, London, United KingdomPrakash P. Punjabi, London, United KingdomMarc Radermecker, Liege, BelgiumNatzi Sakalihasan, Liege, BelgiumMaurice Sarano, Rochester, USAPilar Tornos, Barcelona, SpainPhilippe Unger, Brussels, BelgiumNico Van de Veire, Gent, BelgiumIsidre Villacosta, Madrid, Spain
Scientific program endorsed by the EACVI and by the ESC Working Group on Valvular Heart Diseases
FacultyJutta Bergler-Klein, Vienna, AustriaAlain Berrebi, Paris, FranceBernard Cosyns, Braine-L’Alleud, BelgiumMichele De Bonis, Milan, ItalyJean-Olivier Defraigne, Liege, BelgiumLaurent De Kerchove, Woluwe-Saint-Lambert, BelgiumVictoria Delgado, Leiden, The NetherlandsAlessandro Della Corte, Naples, ItalyErwan Donal, Rennes, FranceGilles Dreyfus, MonacoRaluca Elena Dulgheru, Brussels, BelgiumArturo Evangelista Masip, Barcelona, SpainMadalina Garbi, London, United KingdomAriana González-Gómez, Madrid, SpainBernard Iung, Paris, FranceJoëlle Kefer, Brussels, BelgiumPhilippe Kolh, Liege, BelgiumGiovanni La Canna, Milan, ItalyVictor Legrand, Liege, Belgium
Julien Magne, Limoges, FranceGérald Maurer, Vienna, AustriaThomas Modine, Lille, FranceJean-Luc Monin, Créteil, FranceCécile Oury, Liege, BelgiumAlessandro Parolari, Milan, ItalyAgnes Pasquet, Brussels, BelgiumPhilippe Pibarot, Quebec, CanadaLuc Piérard, Liege, BelgiumBernard Prendergast, London, United KingdomPrakash P. Punjabi, London, United KingdomMarc Radermecker, Liege, BelgiumNatzi Sakalihasan, Liege, BelgiumMaurice Sarano, Rochester, USAPilar Tornos, Barcelona, SpainPhilippe Unger, Brussels, BelgiumNico Van de Veire, Gent, BelgiumIsidre Villacosta, Madrid, Spain
Synoptic
THURSDAY MARCH 10 FRIDAY MARCH 1108:30 Opening ceremony
Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib, José Luis Zamorano, Raphael Rosenhek
08:30 Innovation: new therapeutic approaches of valve disease Victoria Delgado, Luc Piérard
08:40 Symposium: the changing environment of valve disease Patrizio Lancellotti, José Luis Zamorano
09:00 Keynote LectureArturo Evangelista Masip, Natzi Sakalihasan
09:40 Improving risk stratification in asymptomatic mitral regurgitationJean-Olivier Defraigne, Jutta Bergler-Klein
09:55 Keynote lecture Gilles Dreyfus, Gilbert Habib
10:15 Coffee break in the exhibition hall
10:45 Controversies in aortic regurgitationVictor Legrand, Alain Berrebi
11:10 Coffee break in the exhibition hall
11:25 Industry symposium
Accuracy in valve measurements, what are the new trends?
11:40 Industry symposium
Does MitraClip have a survival benefit?12:25 Lunch break in the exhibition hall 12:40 Industry symposium
13:10 Lunch break in the exhibition hall
13:25 ESC 2015 guidelines. Endocarditis: evolution or revolution?Luc Piérard, Patrizio Lancellotti
14:05 Seminar TAVI: minimizing complicationsPatrizio Lancellotti, Gerald Maurer
14:45 Short Communications. Challenges in aortic stenosisAgnes Pasquet, Ariana González-Gómez
15:20 Challenges in the management secondary mitral regurgitationPrakash P. Punjabi, Michele De Bonis, Gilbert Habib16:00 Coffee break in the exhibition hall
16:30 Case presentations: challenges in infective endocarditisGilbert Habib, José Luis Zamorano
16:35 Closing remarks and awards ceremonyPatrizio Lancellotti, Khalil Fattouch, Gilbert Habib,
José Luis Zamorano, Raphael Rosenhek
17:30 Keynote lectureKhalil Fattouch, Arturo Evangelista Masip
18:00 e-Posters competition19:10 End of the sessions
www.eurovalvecongress.com
Thursday March 10, 2016
08:00 Welcome coffee in the exhibition hall
08:30 Opening ceremony Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib,
José Luis Zamorano, Raphael Rosenhek
08:40 Symposium: the changing environment of valve disease Chairmen: Patrizio Lancellotti, José Luis Zamorano08:40 The epidemic of valvular disease, Maurice Sarano09:00 Comorbidities and multiple valves: new challenges, Bernard Prendergast 09:20 The heart team and the heart valve clinic, Raphael Rosenhek09:40 Round table discussion with expert’s panel:
Luc Piérard, Philippe Pibarot, Jean-Luc Monin
09:55 Keynote lecture Chairmen: Gilles Dreyfus, Gilbert Habib09:55 Should we operate on tricuspid valve at the time of left-sided valve surgery?
Giovanni La Canna10:05 Round table discussion with expert’s panel:
Philippe Kolh, Khalil Fattouch, Nico Van de Veire, Alain Berrebi
10:15 Coffee break in the exhibition hall
10:45 Controversies in aortic regurgitation Chairmen: Victor Legrand, Alain Berrebi10:45 Paravalvular regurgitation is a risk factor following TAVI, Philippe Pibarot 11:05 Mild paravalvular regurgitation is not a risk factor following TAVI,
Thomas Modine
11:25 Industry symposium Accuracy in valve measurements, what are the new trends? 11:25 2D Pitfalls in measurements in Mitral Regurgitation, Gilbert Habib 11:40 How 3D can help, José Luis Zamorano 11:55 The aortic valve. Do we need 3D? Ariana González-Gómez 12:10 Do not forget left ventricle in valvulopathies, Julien Magne
12:25 Lunch break in the exhibition hall
13:25 ESC 2015 guidelines. Endocarditis: evolution or revolution? Chairmen: Luc Piérard, Patrizio Lancellotti13:25 Prophylaxis, Bernard Iung13:40 Embolic risk, Patrizio Lancellotti13:55 Diagnostic strategy, Pilar Tornos14:10 Endocarditis team and surgical indications, Gilbert Habib14:25 Round table discussion with expert’s panel
Prakash P. Punjabi, Maurice Sarano, Raluca Elena Dulgheru, Philippe Unger
14:45 Short Communications. Challenges in aortic stenosis Chairmen: Agnes Pasquet, Ariana González-Gómez14:45 Why and what to say to the interventionists? José Luis Zamorano15:00 Should we move toward low risk AS patients with TAVI? Joëlle Kefer 15:15 SAVR or TAVI in patients with previous CABG? Marc Radermecker 15:30 Is TAVI better than SAVR in patients with LV dysfunction? Philippe Pibarot 15:45 ”Valve in Valve” interventions: which is the appropriate patient to select? TBC
16:00 Coffee break in the exhibition hall
16:30 Case presentations: challenges in infective endocarditis Chairmen: Gilbert Habib, José Luis Zamorano 16:30 Endocarditis in the intensive care, Bernard Cosyns16:45 Pacemaker lead endocarditis, Isidre Villacosta17:00 TAVI endocarditis, Gilbert Habib17:15 Marantic endocarditis, Erwan Donal
17:30 Keynote lecture Chairmen: Khalil Fattouch, Arturo Evangelista Masip 17:30 Aortic valve repair: state of the art? Laurent De Kerchove17:45 Round table discussion with expert’s panel
Natzi Sakalihasan, Alain Berrebi, Alessandro Della Corte
18:00 Eposters competition (p 8-11) Chairmen: Erwan Donal, Bernard Cosyns
www.eurovalvecongress.com
Friday March 11, 2016
08:00 Welcome coffee in the exhibition hall
08:30 Innovation: new therapeutic approaches of valve disease Chairmen: Victoria Delgado, Luc Piérard08:30 Percutaneous mitral valve repair, Khalil Fattouch08:50 Round table discussion with expert’s panel
Jose Luis Zamorano, Thomas Modine, Ariana González-Gómez
09:00 Keynote Lecture Chairmen: Arturo Evangelista Masip, Natzi Sakalihasan09:00 The bicuspid aortic valve, Jean-Luc Monin09:20 Round table discussion with expert’s panel
Agnes Pasquet, Khalil Fattouch
09:40 Improving risk stratification in asymptomatic mitral regurgitation Chairmen: Jean-Olivier Defraigne, Jutta Bergler-Klein09:40 Stress echocardiography, Raluca Elena Dulgheru09:55 Neuro-hormones, Julien Magne10:10 Myocardial fibrosis by MRI, Victoria Delgado10:25 Watchful waiting? Raphael Rosenhek10:40 Current gold standard in primary MV repair: importance of patient selection,
Alessandro Parolari10:55 Round discussion with expert’s panel
Cécile Oury, Madalina Garbi
11:10 Coffee break in the exhibition hall
11:40 Industry symposium Does MitraClip have a survival benefit? Chairman: José Luis Zamorano11:40 Introduction, José Luis Zamorano11:50 Who can benefit from the MitraClip Therapy? Philippe Debonnaire12:00 Does MitraClip have a survival benefit? Martin Swaans12:10 Patient management after MitraClip Therapy, Victoria Delgado12:20 Conclusions, José Luis Zamorano
12:40 Industry symposium Anatomical intelligence in Ultrasound, how technology meets clinical practice Endocarditis, Gilbert Habib MV, the 3D perspective, Patrizio Lancelloti HM and EF, clinical scenarios, José Luis Zamorano Fusion imaging in the Cath Lab, the real deal? José Luis Zamorano
13:10 Lunch break in the exhibition hall
14:05 Seminar TAVI: minimizing complications Chairmen: Patrizio Lancellotti, Gerald Maurer14:05 Vascular access, Joëlle Kefer14:20 Stroke Michael, Thomas Modine14:35 Permanent pacing, Joëlle Kefer14:50 Paravalvular leak, José Luis Zamorano15:05 Round discussion with expert’s panel
Luc Piérard, Ariana González-Gómez
15:20 Challenges in the management secondary mitral regurgitation Chairmen: Michele De Bonis, Gilbert Habib15:20 Moderate or severe? Khalil Fattouch15:35 Guidelines in perspective? Luc Piérard15:50 Is there yet a place for surgical repair? Michele De Bonis16:05 Reshape/Coapt: do we need more? Jose Luis Zamorano16:20 Round discussion with expert’s panel
Khalil Fattouch, Jutta Bergler-Klein
16:35 Closing remarks and awards ceremony Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib,
José Luis Zamorano, Raphael Rosenhek
www.eurovalvecongress.com
ePosters competition
18:00 Novel design for bileaflet mechanical heart valves and its hemodynamic performance under physiological condition
Nima Mirkhani1, Mohammad Reza Davoudi2, Pedram Hanafizadeh1, Daryoosh Javidi3, Niloofar Saffarian4
1. University of Tehran, Islamic Republic of Iran
2. Katholieke Universiteit Leuven, Belgium
3. Department of Cardiac Surgery, Pars Hospital, Tehran, Islamic Republic of Iran
4. Cardiovascular Department, Pars Hospital, Tehran, Islamic Republic of Iran
18:03 Heart sarcoma invasive mitral valve Redha Lakehal, Aimer Farid, Bouharagua Rabeh, Boutamina Lilya,
khacha khaled, Boukharoucha Radouane, Bendjaballah Soumaya, Aziza Baya, Brahami Abdelmalek
Ehs el riadh, CONSTANTINE, Algeria
18:06 Thrombosis of heart valve prosthesis in pregnant women Redha Lakehal, Boukharoucha Radouane, Aimer Farid, Bouharagua Rabeh,
Babouri Abdelrahmen, Boutamina Lilya, Aziza Baya, Bendjaballah Soumaya, Brahami Abdelmalek
Ehs el riadh, CONSTANTINE, Algeria
18:09 Prosthetic valve thrombosis Redha Lakehal, Boukharoucha Radouane, Aimer Farid, Bouharagua Rabeh,
Brahami Abdelmalek Ehs el riadh, CONSTANTINE, Algeria
18:12 Aortic valve repair versus replacement in laubry pezzi syndrome Redha Lakehal, Bouharagua Rabeh, Aimer Farid, Boukharoucha Radouane,
Brahami Abdelmalek Ehs el riadh, CONSTANTINE, Algeria
18:15 Epidemiological and clinical aspects of 88 cases with rheumatic mitral valve disease (RMD)
Noura Elazaoui, Leila Azzouzi, Malika Noureddine, Rachida Habbal CHU Ibn Rochd, Casablanca, Morocco
18:18 Brucella tricuspid endocarditis Redha Lakehal, Aimer Farid, Bouharagua Rabeh, Boukharoucha Radouane,
Boukharoucha Radouane Ehs el riadh, CONSTANTINE, Algeria
18:21 Posterior aortic enlargement in women with aortic annulus at 15 mm Redha Lakehal, Aimer Farid, Bouharagua Rabeh, Boukharoucha Radouane,
Brahami Abdelmalek, Boukharoucha Radouane, Brahami Abdelmalek Ehs el riadh, CONSTANTINE, Algeria
18:24 Rheumatic mitral stenosis in adult people in Casablanca (Morocco) Noura Elazaoui, Leila Azzouzi, Malika Noureddine, Rachida Habbal CHU Ibn Rochd, Casablanca, Morocco
18:27 Transient acute mitral regurgitation (TAMR): a new entity responsible for acute heart failure in patients with preserved left ventricular ejection fraction
Olivier Milleron1, Claire Bouleti1, Serge Mazouz2, Eric Brochet1, Whalid Ghodbane3, David Messika-Zeitoun1, Simon Cattan2, Alec Vahanian1, Bernard Iung1, Guillaume Jondeau1
1. Service de Cardiologie Hopital Bichat, Paris, France
2. Service de Cardiologie GHI Le Raincy-Montfermeil, France
3. Service de Chirurgie Cardiaque. Hôpital Bichat, Paris, France
18:30 Investigation of aortic mechanical heart valve effects on the coronary arteries flow rate and potential risk of the atherosclerosis
Nima Mirkhani1, Mohammad Reza Davoudi2, Pedram Hanafizadeh1, Daryoosh Javidi3, Niloofar Saffarian4
1. University of Tehran, Islamic Republic of Iran
2. Katholieke Universiteit Leuven, Belgium
3. Department of Cardiac Surgery, Pars Hospital, Tehran, Islamic Republic of Iran
4. Cardiovascular Department, Pars Hospital, Tehran, Islamic Republic of Iran
18:33 Stress echocardiography: a very useful test in the management of patients with mitral valve stenosis
Oriol de Diego Soler, Elena Ferrer Sistach, Nuria Vallejo Camazon, Jorge Lopez-Ayerbe, Albert Teis Soley, Francisco Gual Capllonch, Silvia Serrano Garcia, Eva Bernal Labrador, Gladys Junca Puig, Antoni Bayes-Genis
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
18:36 Tricuspid tissue valve re-operation in patient with a normally functioning mechanical mitral valve
Sofija Popevska, Darko Anic University Clinic for Cardiac Surgery Rebro, Zagreb, Croatia
18:39 Durability of mechanical mitral prosthesis: do we test the time? Sofija Popevska University Clinic for Cardiac Surgery Rebro, Zagreb, Croatia
18:42 Fusion of x-ray and real time echocardiography during TAVI Ilaria Boretti, Ariana González-Gómez, Covadonga Fernández-Golfín,
Luisa Salido-Tahoces, Rosa Ana Hernández-Antolín, Eduardo Casas-Rojo, Rocio Hinojar-Baydes, José Luis Zamorano
Department of Cardiology-Ramon y Cajal University Hospital, Madrid, Spain
Sign up under the ‘Stay Alert’ heading at: ehjcimaging.oxfordjournals.org
Stay alertKeep up to date with the highest quality material,
both scientific and clinical, from all areas of cardiovascular imaging with email table of
contents alerts from the European Heart Journal – Cardiovascular Imaging
At the heart of Cardiology
ePosters competition
18:45 Ball thrombus with recent cardioembolic stroke: case report and brief review of the literature
Noura Elazaoui, Leila Azzouzi, Malika Noureddine, Rachida Habbal CHU Ibn Rochd, Casablanca, Morocco
18:48 Characteristics and outcomes of asymptomatic severe aortic stenosis patients with preserved left ventricular ejection fraction according to the flow and gradient classification
Carlos Izurieta, Juan Manuel Monteagudo-Ruiz, Ariana González-Gómez, Covadonga Fernández-Golfin, Ana García-Martín, Rocío Hinojar-Baydes, Eduardo Casas-Rojo, José Julio Jiménez-Nacher, José Luis Zamorano
Hospital Universitario Ramón y Cajal, Madrid, Spain
18:51 Prosthetic pulmonary valve and pulmonary conduit endocarditis: clinical, microbiological and echocardiographic features in adults
William Miranda, Heidi Connolly, Crystal Bonnichsen, Daniel DeSimone, Joseph Dearani, Joseph Maleszewski, Kevin Greason, Walter Wilson, Larry Baddour
Mayo Clinic, Rochester, United States
18:54 Emergent surgery in infective endocarditis in a tertiary hospital Nuria Vallejo Camazon1, Xavier Armario1, Oriol de Diego1, Francisco Gual1,
Albert Teis1, Jorge Lopez Ayerbe1, Cinta LLibre1, Lluisa Pedro Botet2, Raquel Nuñez Aragon2, Antoni Bayes Genis1
1. Cardiology. Hospital Germans TRias i Pujol, Barcelona, Spain
2. Infectious Diseases department.Hopsital Germans Trias i Pujol, Badalona, Spain
18:57 Clinical and epidemiological profile of native infective endocarditis in a tertiary center; outcome changes after multidisciplinary team aproach
Nuria Vallejo1, Oriol De Diego1, Xavier Armario1, Lurdes Mateu2, Sonia Molinos3, Elisabet Berastegui4, Elena Ferrer1, Antoni Bayes Genis1
1. Cardiology department. Hospital Germans Trias i Pujol, Badalona, Spain
2. Infectious diseases. Hospital Germans TRias i Pujol, Badalona, Spain
3. Microbiology. Hospital Germans Trias i Pujol, Badalona, Spain
4. Cardiaca Surgery. Hospital Germans TRias i Pujol, Badalona, Spain
19:00 Pseudoaneurysm of valsalva sinus in a brucella infected native aortic valve Daniela Teferici, Edvin Prifti, Amanda Lloji, Lidra Gjyli UHC “Mother Theresa”, Tirana, Albania
19:10 End of the sessions
Sign up under the ‘Stay Alert’ heading at: ehjcimaging.oxfordjournals.org
Stay alertKeep up to date with the highest quality material,
both scientific and clinical, from all areas of cardiovascular imaging with email table of
contents alerts from the European Heart Journal – Cardiovascular Imaging
At the heart of Cardiology
Notes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Information
Congress venue: Hotel Bloom, Brussels, BELGIUMRue Royale 2501210 Brussels, BelgiumPhone: +3222206611www.hotelbloom.com
REGISTRATION DESK OPENING HOURS
Thursday March 10 07.30 - 19.30Friday March 11 07.30 - 17.00
EVENT COORDINATORS’ CONTACTS
Project manager Stéphanie Meyer + 33 646 10 48 26
Managing directorVérane Bergeron Moreau + 33 621 78 87 16
References1. St. Jude Medical. Trifecta™ Valve. Pre-Market Approval Application Summary of Safety and Effectiveness Data. P100029. 2011.2. St. Jude Medical. Trifecta™ Valve. Clinical Compendium. Five-Year Data. 2014. ID-2000385 B EN (06/14).3. Edwards Lifesciences Corporation. Carpentier-Edwards Magna Ease™ Pericardial Aortic Bioprosthesis, Model 3300TFX. Instructions for Use. 2009. Echo follow-up at one year. 4. Medtronic, Inc. (ATS Medical). 3f™ Aortic Bioprosthesis. Pre-Market Approval Application Summary of Safety and Effectiveness Data, P060025. 2008. Echo follow-up at one year.5. Medtronic, Inc. Medtronic Mosaic™ Porcine Bioprosthesis. Pre-Market Approval Application Summary of Safety and Effectiveness Data. P990064. 2000. Echo follow-up at one year.6. CarboMedics, Inc., Sorin. Mitroflow™ Aortic Pericardial Heart Valve. Pre-Market Approval Application Summary of Safety and Effectiveness Data. P060038. 2007. Echo follow-up at one year.7. St. Jude Medical. Trifecta™ Valve. 2010. Data on file.Rx Only Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Indications: The Trifecta™ Valve is indicated as a replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve. Adverse events potentially associated with the use of bioprosthetic heart valves include: angina, cardiac arrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, leak (transvalvular or perivalvular), myocardial infarction, nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other), prosthesis regurgitation, stroke, structural deterioration (calcification, leaflet tear, perforation, or other), thromboembolism and valve thrombosis. It is possible that these complications could lead to reoperation, explantation, permanent disability or death. Long-term low dose aspirin, unless contraindicated, is recommended for all patients with bioprosthetic valves. Long-term anticoagulant therapy, unless contraindicated, is recommended for all patients with bioprosthetic valves who have risk factors for thromboembolism. Please see the Instructions for Use (IFU) for a full description of indications, contraindications, side effects, precautions, warnings and Instructions for Use. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. and its related companies. © 2015 St. Jude Medical, Inc. All Rights Reserved. Product referenced is approved for CE Mark. SJM-TRF-1214-0015(2)b | Item approved for international use.
The Trifecta™ Valve from St. Jude Medical was designed to deliver exceptional hemodynamic performance and durability to stand the test of time. The Trifecta™ Valve consistently mimics the flow of a native healthy heart valve.
Bench testing predicted excellent hemodynamics and durability,1 while clinical data from a prospective multi-center study delivered the proof.2
PROMISE Exceptional hemodynamics
PROVEN The lowest hemodynamic gradients in the market, size-for-size among tissue heart valves1,3-6
PROMISE Excellent durability; 99.2% freedom from SVD at 5 years7
PROVEN 99.7% freedom from SVD at 5 years2
Learn more at sjm.com/trifecta
WHY NOT OFFER YOUR PATIENTS A VALVE PROVEN TO PERFORM LIKE A NATIVE HEALTHY HEART VALVE?
Plenary room
23
4
51
Preview
CloakroomBuffet
Desk
Table futuremeeting
Buffet
office
ACKNOWLEDGEMENTS 2016
Exhibition hallEXHIBITION TIMES Thursday March 10 08.00 - 16.30Friday March 11 08.00 - 14.00
Booth Company
1 Abbott Vascular2 GE Healthcare3 Medtronic4 LivaNova5 St. Jude Medical
Notes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
www.eurovalvecongress.com
ORGANIZATION: divine [id] agency • Stéphanie Meyer: smeyer@divine-id.com • Mob. +33 (0) 646 10 48 26• Vérane Bergeron Moreau: vbergeron@divine-id.com• 17, rue Venture - 13001 Marseille, France• Tel. +33 (0) 491 57 19 60 • Fax +33 (0) 491 57 19 61 • www.divine-id.com
Visa Mdeon n° 16/V2/8598/004974
top related